Biostarks’ at-home test kits are intended for the fast-growing longevity market. Credit: Biostarks Labs / PRNewswire.

Digital health company Biostarks has announced new at-home longevity test kits that leverage the firm’s mass-spectrometry platform.

The base and premium at-home test kits are intended for the fast-growing longevity market.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Planned to be commercialised as early as April, the base longevity at-home test kit is designed to measure intracellular NAD+ and three essential minerals.

Meanwhile, the premium longevity at-home test kit, which is scheduled for launch later this summer, covers more than 30 essential micronutrients, including minerals, vitamins, fatty and amino acids, three hormone markers, and intracellular NAD+.

Biostarks has completed new validation studies with the aim of expanding the test kit’s coverage to include comprehensive measurements of Senescence, Rapamycin levels and two oxidative stress markers.

Biostarks executive chairman Francois Marland said: “We believe our premium longevity test kit is a true novelty and market premiere for any individuals willing to decode their biodata and take a step towards a healthier lifespan.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

“While the project is already funded internally, the commercial prelaunch is an awesome opportunity to engage with the longevity enthusiast’s community, to create broader awareness around at-home test kits solution.”

Both test kits can be used in the comfort of the user’s home.

The digital health company is planning to undertake institutional fundraising in the coming quarter, with the aim of expanding its offering in the corporate wellness space and pursuing new partnerships.

Last year, Biostarks launched its third branch with Biostarks Labs Singapore.

Biostarks Labs Singapore is a 100% subsidiary of Biostarks Labs US, which is owned by Biostarks Group.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact